目的：评价康柏西普治疗湿性年龄相关性黄斑变性(exudative age-related macular degeneration，eAMD)的疗效和安全性，为临床用药提供参考。

方法：计算机检索PubMed数据库、Cochrane图书馆、中国知网(CNKI)和万方医学网，收集建库至2017-11康柏西普和常规疗法治疗eAMD的随机对照研究，提取相关资料并按照修改后的Jadad评分量表评价纳入研究文献的质量，采用RevMan 5.3和Stata 12.0统计软件进行Meta分析。

结果：本研究共纳入12项随机对照研究，合计924例患者。Meta分析结果显示，与对照组相比，康柏西普显著降低随访1、3、6、12mo患者黄斑中心凹视网膜厚度(central macular retinal thickness，CMT)； 显著提高随访3、6mo患者裸视视力及随访6mo生活质量； 提高治疗总有效率，且康柏西普治疗组较对照组远期疗效更好，但两组患者治疗后不良反应发生率比较，差异无统计学意义(P>0.05)。

结论：康柏西普能够显著降低eAMD患者CMT，改善裸视视力，提高生活质量和治疗总有效率，远期疗效较好，且安全性好。

METHODS:We performed a comprehensive search for the randomized controlled trials(RCTs)about conbercept trail group vs control group in the treatment of eAMD published by November, 2017 from PubMed, Cochrane Library, CNKI and Wanfang Database. Studies obtained from eligible database were filtered according to modified Jadad scale, and data were retrieved from those studies for further analysis. Then, we performed a Meta-analysis using RevMan 5.3 and Stata 12.0 statistical software.

RESULTS:A total of 12 RCTs were included, involving 924 patients. The results of Meta-analysis showed that the central macular retinal thickness(CMT)markedly decreased at 1, 3, 6 and 12mo after treatment; visual acuity at 3 and 6mo and quality of life(QOL)at 6mo were significantly improved; total effective rate of treatment at increased, which was statistically different to control group(P<0.05), but rate of adverse reaction was similar(P>0.05). The long-term effect was better than control group.

CONCLUSION:The existing evidence supports that conbercept has good therapeutic efficacy and safety for eAMD. It can significantly reduce the CMT, improve the visual acuity, the quality of life and the total efficiency of treatment, and the long-term effect is better than control group.